10-Q: NovoCure Reports Increased Q2 Revenue Amid Rising Operating Costs and Expanded Clinical Pipeline

NovoCure Limited announced its second quarter 2025 financial results, showing a 6% increase in net revenues to $158.8 million, driven by patient growth and international market expansion, despite a widening net loss and reduced gross margin.

Summary

• Net revenues for the three months ended June 30, 2025, increased by 6% to $158.8 million, up from $150.4 million in the same period of 2024.
• Net revenues for the six months ended June 30, 2025, increased by 9% to $313.8 million, up from $288.9 million in the same period of 2024.
• Gross profit for Q2 2025 was $117.3 million, a slight increase from $115.7 million in Q2 2024, but gross margin decreased to 74% from 77%.
• Operating costs and expenses rose by 5% to $156.9 million in Q2 2025, primarily due to increases in general and administrative expenses (17%) and research, development, and clinical studies (2%).
• Net loss for Q2 2025 widened to $40.1 million, compared to a net loss of $33.4 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, was $74.5 million, compared to $72.1 million in the same period of 2024.
• Adjusted EBITDA for Q2 2025 was a loss of $9.9 million, down from a profit of $1.1 million in Q2 2024.
• Active patients on therapy reached 4,331 worldwide as of June 30, 2025, up from 3,963 in 2024, with significant growth in Optune Lua patients (137 vs. 26).
• Prescriptions received in Q2 2025 totaled 1,741, with Optune Lua prescriptions increasing to 143 from 26 in Q2 2024, while Optune Gio prescriptions slightly decreased.
• Cash, cash equivalents, and short-term investments totaled $911.5 million as of June 30, 2025, a decrease of $48.3 million from December 31, 2024.
• Net cash used in operating activities increased to $51.6 million for the six months ended June 30, 2025, from $33.3 million in the prior year period.
• The company has a $559.8 million 0% Convertible Senior Note due November 1, 2025, which has been reclassified as a current liability.
• Positive results were presented from the Phase 3 PANOVA-3 clinical trial for pancreatic adenocarcinoma and the Phase 3 METIS clinical trial for brain metastases from NSCLC.
• The company plans to file FDA PMA applications for pancreatic cancer in Q3 2025 and complete the METIS full submission by the end of 2025.
• U.S. tariff rate changes are estimated to increase import duties by up to approximately $7 million in 2025, with $1.3 million expensed in Q2 2025.
• A class action lawsuit filed in June 2023 was dismissed by the court on March 18, 2025, and the matter is now closed.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While financial losses widened and margins compressed, the company demonstrated strong revenue growth, significant patient adoption for its key products, and, most importantly, reported positive Phase 3 clinical trial results for two new indications (pancreatic cancer and brain metastases from NSCLC). These clinical advancements represent substantial future growth potential and regulatory milestones. The near-term convertible note maturity and tariff impacts are notable financial headwinds, but the company's cash position and new credit facility provide some liquidity. The overall outlook is cautiously optimistic due to the strong pipeline and commercial traction despite current unprofitability.

Positives

• Net revenues increased by 6% in Q2 2025 and 9% for the six months ended June 30, 2025, demonstrating continued commercial growth.
• Active patient count grew to 4,331 worldwide as of June 30, 2025, indicating increased adoption of TTFields therapy.
• Optune Lua, for NSCLC and MPM, showed significant growth in active patients (137 vs. 26) and prescriptions (143 vs. 26) in Q2 2025, highlighting successful new indication launches.
• The Phase 3 PANOVA-3 clinical trial for pancreatic adenocarcinoma yielded positive results, showing improved median overall survival (16.2 months vs. 14.2 months) and pain-free survival (15.2 months vs. 9.1 months) with TTFields therapy.
• The Phase 3 METIS clinical trial for brain metastases from NSCLC met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression (15.0 months vs. 7.5 months).
• The company is advancing regulatory submissions, with the PANOVA-3 FDA PMA application expected in Q3 2025 and the METIS full submission by the end of 2025.
• The modular PMA shell for the METIS application has been approved by the FDA, and two of three modules have been filed.
• The class action lawsuit filed in June 2023 was dismissed by the court, and the matter is now closed, removing a legal overhang.
• The company secured a new five-year senior secured credit facility of up to $400.0 million, with Tranche A ($100.0 million) funded and Tranche B ($100.0 million) notice of intent to draw given, providing future liquidity options.

Negatives

• Net loss widened to $40.1 million in Q2 2025 from $33.4 million in Q2 2024, and to $74.5 million for the six months ended June 30, 2025, from $72.1 million in the prior year period.
• Gross margin decreased to 74% in Q2 2025 from 77% in Q2 2024, primarily due to higher average array costs and increased tariffs.
• Operating expenses increased by 5% in Q2 2025, outpacing revenue growth and contributing to increased losses.
• Financial income (expenses), net, decreased significantly by 58% in Q2 2025, primarily due to lower interest income and higher foreign exchange expenses.
• Net cash used in operating activities increased by 55% to $51.6 million for the six months ended June 30, 2025, indicating a higher cash burn rate.
• The $559.8 million 0% Convertible Senior Notes are due November 1, 2025, and have been reclassified as a current liability, posing a near-term financial obligation.
• U.S. tariff rate changes are expected to increase import duties by up to $7 million in 2025, impacting cost of revenues and gross margin.
• Cost of revenues per active patient per month (excluding Zai) increased by 10% to $2,970 in Q2 2025, driven by new array roll-out and NSCLC launch costs.
• Optune Gio prescriptions slightly decreased in Q2 2025 compared to the prior year period.

Risks

• The conflict in Israel poses a potential risk to the supply chain, as some suppliers are single-source, and securing second-source suppliers on a timely basis is not assured.
• Changes in U.S. tariff rates, including potential 30% tariffs on goods from Mexico and the European Union, could significantly increase import duties and negatively impact cost structure.
• The company expects operating expenses to continue increasing and potentially outpace gross profit, which may necessitate raising additional capital to fund operations.
• Reimbursement for Optune Lua for NSCLC and MPM indications is currently recognized upon cash collection due to a lack of sufficient claims history, which can delay revenue recognition.
• The company's ability to secure and maintain adequate coverage from third-party payers for current and future indications of its products is crucial for revenue generation.
• The company's cash needs and ability to obtain additional financing are subject to market conditions and operational performance.
• The success of ongoing clinical trials (TRIDENT, KEYNOTE D58, LUNAR-2, LUNAR-4, PANOVA-4) is critical for expanding product indications and future revenue growth.
• The company's ability to acquire and manufacture adequate supply of its products from third-party suppliers is essential for commercialization.

Future Outlook

The company anticipates expanding its clinical pipeline to study TTFields therapy for additional solid tumor indications and in combination with other cancer treatments. It expects to file its PANOVA-3 FDA PMA application in the third quarter of 2025 and complete the METIS full submission by the end of 2025. Operating expenses are projected to continue increasing over the next several years, potentially outpacing gross profit as the company prepares to expand into new indications. The company is actively evaluating opportunities to expand its international footprint and pursuing coverage policies with payers for Optune Lua.

Management Comments

• We are actively evaluating opportunities to expand our international footprint.
• We are actively pursuing coverage policies with payers to expand access to Optune Lua for patients with NSCLC and MPM and in the meantime we will bill and seek reimbursement from payers on an individual case basis, as applicable.
• We believe the physical mechanisms of action behind TTFields therapy may be broadly applicable to solid tumor cancers.
• We anticipate expanding our clinical pipeline over time to study the safety and efficacy of TTFields therapy for additional solid tumor indications and for use together with other cancer treatment modalities.
• We believe we possess global commercialization rights to our Products in oncology and are well-positioned to extend those rights into the future as we continue to find innovative ways to improve our Products.
• We view our operations and manage our business in one operating segment.
• We intend to take actions that prioritize growth and maintain financial health and flexibility as we position our company for future profitability.
• We believe our cash, cash equivalents and short-term investments as of June 30, 2025 are sufficient for our operations for at least the next 12 months based on our existing business plan and our ability to control the timing of significant expense commitments.

Industry Context

NovoCure operates in the highly competitive and regulated oncology sector, specifically in the niche of Tumor Treating Fields (TTFields) therapy for solid tumor cancers. The positive clinical trial results for pancreatic cancer (PANOVA-3) and brain metastases from NSCLC (METIS) position the company for potential expansion into significant new indications, which could broaden its market reach beyond its current GBM, NSCLC, and MPM approvals. The focus on expanding international markets and securing payer coverage for newer indications aligns with industry trends of globalizing innovative therapies and navigating complex reimbursement landscapes. The company's continued investment in R&D and product enhancement reflects the industry's drive for continuous innovation and improved patient outcomes. The challenges related to tariffs and supply chain resilience are common across global medical device manufacturers.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A putative class action lawsuit filed in June 2023, alleging material misstatements regarding the LUNAR clinical trial results, was dismissed by the court on March 18, 2025. The plaintiffs did not appeal, and the matter is now closed.

Stakeholder Impact

• Shareholders: Face increased net losses and a decrease in gross margin, but benefit from positive clinical trial results for new indications and growth in active patients, which could drive long-term value. The upcoming convertible note maturity and potential capital raise are key financial considerations.
• Patients: Benefit from continued commercialization of Optune Gio and Optune Lua, and the potential for new treatment options for pancreatic cancer and brain metastases from NSCLC based on positive clinical trial data and upcoming regulatory submissions.
• Employees: Impacted by the adoption of new incentive and share purchase plans, which can affect compensation and ownership opportunities. The company's growth and expansion into new indications may create new opportunities.
• Third-party Payers: The company is actively pursuing coverage policies for Optune Lua, indicating ongoing engagement to secure reimbursement, which is critical for patient access and company revenue.
• Suppliers: The company is increasing stock levels and seeking second-source suppliers outside Israel to mitigate supply chain risks, which could impact existing supplier relationships and create opportunities for new suppliers.

Next Steps

• File FDA PMA application for pancreatic cancer (PANOVA-3) in Q3 2025.
• Complete full FDA PMA submission for brain metastases from NSCLC (METIS) by the end of 2025.
• Close the Tranche B Loan of $100.0 million on September 26, 2025.
• Continue to pursue the use of Products for the treatment of indications other than GBM, NSCLC, and MPM.
• Actively evaluate opportunities to expand international footprint.
• Actively pursue coverage policies with payers to expand access to Optune Lua for NSCLC and MPM.
• Continue product development programs to optimize TTFields delivery and enhance patient ease of use.
• Focus on opportunities to mitigate negative tariff impacts and increase efficiencies and scale within the supply chain, including evaluating new materials, manufacturers, and processes.

Key Dates

Recommendation

While NovoCure's Q2 2025 financial results show widening losses and a declining gross margin, the significant positive clinical trial data for PANOVA-3 (pancreatic cancer) and METIS (brain metastases from NSCLC) are strong catalysts for future growth and market expansion. The increase in active patients, particularly for Optune Lua, demonstrates commercial traction. However, the near-term maturity of the $559.8 million convertible note and the increasing cash burn rate present financial challenges. The company's liquidity position is adequate for the next 12 months, and the new credit facility provides some flexibility. Given the strong clinical pipeline and long-term potential balanced against current unprofitability and near-term debt obligations, a 'hold' recommendation is appropriate for investors to monitor the progress of regulatory submissions, the resolution of the convertible note, and the impact of tariff changes on profitability.

Keywords

Tumor Treating Fields, TTFields, Optune Gio, Optune Lua, Glioblastoma, GBM, Non-Small Cell Lung Cancer, NSCLC, Malignant Pleural Mesothelioma, MPM, Pancreatic Adenocarcinoma, Brain Metastases, Oncology, Medical Device, Clinical Trials, PANOVA-3, METIS, FDA PMA, SEC Filing, Quarterly Report, Financial Results, Biopharma, Cancer Treatment, Active Patients, Prescriptions, Convertible Notes, Credit Facility, Tariffs, Supply Chain